Critical care clinical trials getting off the roller coaster

Chest

Volumn 142, Issue 3, 2012, Pages 563-567

  Goodwin, Andrew J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CORTISONE; DEXAMETHASONE; DROTRECOGIN; GLUCOSE; INSULIN; METHYLPREDNISOLONE; PLACEBO;

ADULT RESPIRATORY DISTRESS SYNDROME; APACHE; ARTIFICIAL VENTILATION; BACTEREMIA; CLINICAL STUDY; CRITICAL ILLNESS; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; INSULIN TREATMENT; INTENSIVE CARE; LENGTH OF STAY; MORTALITY; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SEPTIC SHOCK; STEROID THERAPY; STREPTOCOCCAL PHARYNGITIS;

EID: 84865858360     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0519     Document Type: Note

References (34)

1. Halpern NA, Pastores SM. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010;38(1):65-71.
2. Annane D, Sé bille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [published correction appears in JAMA. 2008;300(14):1652]. JAMA. 2002;288(7):862-871.
3. Sprung CL, Annane D, Keh D, et alCORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
4. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359-1367.
5. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449-461. (Pubitemid 43200296)
6. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-1297.
7. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
8. Abraham E, Laterre PF, Garg R, et al Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332-1341. (Pubitemid 41362701)
9. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock [published online ahead of print May 22, 2012]. N Engl J Med. doi:10.1056/NEJMoa1202290.
10. Perla D, Marmorston J. Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology. 1940;27:367.
11. Hahn EO, Houser HB, Rammelkamp CH Jr, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and poststreptococcal complications. J Clin Invest. 1951;30(3):274-281.
12. Weitzman S, Berger S. Clinical trial design in studies of corticosteroids for bacterial infections. Ann Intern Med. 1974;81(1):36-42.
13. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976;184(3):333-341.
14. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987;317(11):659-665.
15. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653-658. (Pubitemid 17138189)
16. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet. 1991;337(8741):582-583.
17. Annane D, Sébille V, TrochéG, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283(8):1038-1045. (Pubitemid 30112218)
18. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig Med. 1997;45(2):50-56. (Pubitemid 127453337)
19. Said G, Goulon-Goeau C, Slama G, Tchobroutsky G. Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus. A clinical and pathological study. N Engl J Med. 1992;326(19):1257-1263.
20. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25(7):1115-1124. (Pubitemid 27310249)
21. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet. 1998;351 (9107):929-933. (Pubitemid 28138465)
22. Silva E, de Figueiredo LF, Colombari F. Prowess-shock trial: a protocol overview and perspectives. Shock. 2010;34 (suppl 1):48-53.
23. Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263(10):1405-1408. (Pubitemid 20069949)
24. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867-872.
25. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315(7109):640-645. (Pubitemid 27387174)
26. Dubben HH, Beck-Bornholdt HP. Systematic review of publication bias in studies on publication bias. BMJ. 2005;331(7514):433-434.
27. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med. 2009;6(9):e1000144.
28. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342(18):1301- 1308.
29. Rivers E, Nguyen B, Havstad S, et alEarly Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
30. Collard HR, Saint S, Matthay MA. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med. 2003;138(6):494-501.
31. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471-1477. (Pubitemid 30318270)
32. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338 (6):347-354. (Pubitemid 28083906)
33. Stewart TE, Meade MO, Cook DJ, et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med. 1998;338(6):355-361. (Pubitemid 28083907)
34. Reporter's notebook: an interview with James P. Kiley, PhD, director, Division of Lung Diseases, NHLBI. Advance for Respiratory Care &Sleep Medicine website. http://respiratorycare-sleep-medicine.advanceweb.com/Article/ ARDSnet-Qand-A.aspx. Accessed December 2011.